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gery.4 The authors also mentioned use of
multiple variables that might or might not
be clinically relevant and assigned propen-
sity scores in the outcome models to adjust
for antifibrinolytic use. I believe that such
an analysis is suboptimal to propensity
score matching in quantiles. Surgeons need
to take a closer look and revisit the data
published in this article before banning
aprotinin from their practice.
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About the activation of the
coagulation system during on-pump
and off-pump coronary surgery and
the use of antifibrinolytic drugs
To the Editor:
The results of the study by Paparella
and colleagues1 recently published in the
Journal confirm part of the observations
described in previous reports addressing
the activation of coagulation and fibrinoly-
sis in coronary surgery performed with
(ONCAB) or without (OPCAB) cardiopul-
monary bypass (CPB). However, some of
the statements contained in their “Discus-
sion” section deserve critical consideration.
Because no difference in tissue factor (TF)
“production” was observed in the 2 groups
of patients while prothrombin fragment 1.2
levels were higher in patients undergoing
ONCAB, the authors state that the extrinsic
pathway of coagulation should not be con-
sidered the only trigger for thrombin for-
mation during CPB. Although the intrinsic
pathway might also play a role in thrombin
formation during CPB, the observation of
circulating levels of TF that are not signif-
icantly different does not per se demon-
strate a similar activation of the extrinsic
pathway of coagulation in the 2 groups of
patients. TF is a transmembrane protein
expressed by white blood cells under con-
ditions of activation, and deposition of
such cells in the CPB circuit has been
shown before.2 Therefore plasma levels of
TF might not reflect the true “exposure” of
TF to circulating blood. The authors state
that in patients undergoing OPCAB, ad-
ministration of a heparin dose similar to the
one used during CPB (300 U/kg) elimi-
nates the production of thrombin during the
time of the operation. “Elimination” of
thrombin production would lead to severe
bleeding, which cannot obviously be the
aim of heparin administration. The authors
also state that platelet function, as analyzed
by using an in vitro bleeding test (PFA-
100), is better preserved during OPCAB
surgery than during CPB and that the lack
of CPB and cardiotomy suction, together
with the reduced formation of thrombin,
might explain why platelet function is pre-
served in patients undergoing OPCAB. The
PFA-100 is influenced by the platelet count
and the hematocrit level, which are both
obviously higher in patients undergoing
OPCAB, and by von Willebrand factor lev-
els, which are known to increase postoper-
atively. Thus the PFA-100 can hardly be
considered validated in evaluating platelet
function in the setting of cardiac surgery.
Despite the observation of a similar post-
operative “hypercoagulable” pattern in the
2 groups of patients, the authors also em-
phasize that D-dimer levels are lower in
patients undergoing OPCAB, advising
against the use of antifibrinolytic drugs,
which might increase the risk of vein graft
occlusion in this surgical setting. These
conclusions are in disagreement with the
results previously reported by our group3
and with the clinical observations of the
authors. A similar, although not negligible,
24-hour postoperative bleeding value was
recorded in the 2 groups (total blood loss:
ONCAB, 861.2  340.3 mL; OPCAB,
933.7 382.6 mL). In a pilot study carried
out in patients not receiving antifibrinolytic
drugs, we recorded an average total blood
loss of 850 mL in patients undergoing
ONCAB and 750 mL in patients undergo-
ing OPCAB.3 In a larger study powered to
detect differences in bleeding between pa-
tients undergoing ONCAB and patients un-
dergoing OPCAB randomized to receive
tranexamic acid or placebo, the average
total blood loss was 754 mL and 552 mL in
patients undergoing ONCAB off or on
tranexamic acid treatment and 654 and 375
mL in patients undergoing OPCAB off or
on tranexamic acid treatment, respectively,
with a significant reduction in bleeding for
both groups in the tranexamic acid arm
(P  .006).4 In both studies the difference
in total bleeding observed between patients
undergoing ONCAB and patients undergo-
ing OPCAB was obviously affected by the
different amount of heparin infused in the 2
groups (3 times higher in patients undergo-
ing ONCAB). Moreover, in the same study
we found that tranexamic acid administra-
tion not only significantly reduces periop-
erative bleeding and the need for allogeneic
transfusions both in patients undergoing
ONCAB and patients undergoing OPCAB
but also modulates inflammation, particu-
larly in OPCAB surgery.4 In view of these
certain advantages of antifibrinolytic drugs
and of a procoagulant postoperative state of
uncertain significance,5,6 the advice against
the use of antifibrinolytic agents is, in our
opinion, at least debatable.
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Reply to the Editor:
Thank you for the invitation to respond to
Dr Casati and colleagues’ letter. We used
an in vitro bleeding time test (Platelet
Function Analyzer [PFA]-100) to evaluate
platelet function perioperatively at 7 differ-
ent observation times. Only one of these
observations was performed during cardio-
pulmonary bypass with hemodiluted pa-
tients. Fibrinolytic activity can indirectly
be measured, evaluating the balance be-
tween the promoter of fibrinolysis (tissue-
type plasminogen activator) and its inhibi-
tor (plasminogen activator inhibitor 1). In
our study1 we observed that tissue-type
plasminogen activator levels are not in-
creased, whereas plasminogen activator in-
hibitor 1 and D-dimer levels are modestly
increased after off-pump coronary artery
bypass (OPCAB) surgery. These data
would suggest that fibrinolysis is not par-
ticularly activated during OPCAB surgery.
Dr Casati states that an antifibrinolytic
agent should be used in patients undergo-
ing OPCAB surgery because he has previ-
ously demonstrated2 a significant reduction
of postoperative bleeding in patients under-
going OPCAB treated with tranexamic acid
(25 patients) compared with patients under-
going OPCAB treated with placebo (25
patients). In their study Casati and col-
leagues2 were not able to show a significant
difference in blood product transfusion be-
tween the groups. Moreover, hemoglobin
and hematocrit values reported up to 24
hours postoperatively were not influenced
by tranexamic acid administration. As we
remarked in our article, recent studies with
angiographic control have shown a worse
graft patency in patients operated on by
means of the OPCAB technique compared
with those undergoing the on-pump tech-
nique. Inaccurate anastomosis rather than a
procoagulative state is probably the main
cause of these results; nevertheless, this has
not been proved. Although numerous in-
vestigators have documented profound
short-term and midterm coagulative-
fibrinolytic and inflammatory alterations in
patients undergoing coronary artery bypass
grafting surgery, there are no clinical stud-
ies that evaluated prospectively and on an
appropriate number of patients the value of
prothrombotic and proinflammatory mark-
ers in predicting early graft occlusion. Ex-
isting studies are small and produced con-
flicting results: Poston and associates3
reported that thrombelastography and
whole blood aggregometry do not predict
graft occlusion; however, in another study
the same authors showed a reduction in
platelet sensitivity to aspirin by means of
both thrombelastography and aggregom-
etry in patients with early graft failure.4
Karski and coworkers5 have recently dem-
onstrated that tranexamic acid administra-
tion does not worsen early saphenous graft
patency in patients receiving on-pump cor-
onary artery bypass grafting. However, our
results show that in the first 24 hours after
the operation, patients undergoing on-
pump operations and OPCAB have a dif-
ferent activation of the coagulation and fi-
brinolytic systems. Consequently, what is
safe for patients undergoing on-pump op-
erations might not be safe for those under-
going OPCAB. The reason why we operate
on patients with coronary artery disease is
to improve their long-term outcome while
trying to minimize their perioperative risk.
Considering that postoperative bleeding is
not a serious complication after OPCAB
surgery, we agree with Dr Casati’s final
remarks: “Further randomized studies, en-
rolling larger numbers of patients, are
needed to confirm the antiinflammatory ef-
fects of TA and to rule out the potential risk
of thrombotic complications.”2
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A new surgical paradigm: Hybrid
open and endovascular repair of the
ascending aorta and aortic arch for
acute type A dissection
To the Editor:
I read with interest the editorial by
Dobrilovic and Elefteriades1 reflecting on
the potential future application of simulta-
neous hybrid endoluminal graft repair of
the descending thoracic aorta after tradi-
tional open surgical repair of the ascending
aorta and aortic arch for acute type A aortic
dissection, as discussed in the article by
Uchida and associates.2
Although the results reported by Uchida
and associates2 are noteworthy, stabilizing
the true lumen in the descending thoracic
aorta with an endoluminal graft after total
aortic arch replacement may not be the final,
or best, approach for acute type A aortic
dissection. The current surgical paradigm is
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